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Abstract 
 
 Prostate cancer is a prevalent, worldwide problem among male adults. This  
 
literature review, “Examining the Efficacy of Screening with Prostate-Specific Antigen  
 
Testing in Reducing Prostate Cancer Mortality,” focuses on a safe and effective  
 
screening test for detecting prostate cancer in its early stages—prostate-specific antigen  
 
testing—and seeks to answer the clinical question, “Does screening with PSA testing for 
the early detection of prostate cancer in males ages 50-80 years significantly reduce 
prostate cancer mortality?” A literature search of peer-reviewed articles within the last 
fifteen years on databases such as CINAHL and Pub Med was conducted to find five 
articles that pertained to the clinical question. An analysis and synthesis of the research 
articles provided promising yet not conclusive evidence that prostate-specific antigen 
testing significantly reduces the absolute risk of prostate cancer morality. Further 
research is needed to provide more substantial evidence to support the use of prostate-
specific antigen testing in clinical practice.  
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Introduction 
 
The efficacy of screening with prostate-specific antigen (PSA) testing for the 
early detection of prostate cancer is a topic of heated debate in the medical world.  
Articles have recently been published highlighting the harms and risks of PSA testing. 
One of the most recent, a systematic review released by the U.S. Preventive Services 
Task Force (USPSTF), reveals findings that confound the issue further. For example, the 
USPSTF found PSA testing detects a modest amount of prostate cancers; however, it may 
lead to overdiagnosis of prostate cancer and further risks such as pain secondary to 
prostate biopsy (2008, pp. 185-187). In addition to this evidence, the USPSTF found 
most prostate cancers detected with PSA testing will not be harmful to the patient during 
their lifetime (2008, p. 187). Due to recently published articles and the 2008 positional 
statement of the USPSTF, screening for prostate cancer has become a paradox. To 
address the current debate about PSA testing and its role in screening for prostate cancer, 
it is pertinent to ask the following: Does screening with PSA testing for the early 
detection of prostate cancer in males ages 50-80 years significantly reduce prostate 
cancer mortality?  
Discussion of Prostate Cancer and Prostate Cancer Screening 
The high prevalence of prostate cancer and the clinical importance of determining 
whether current screening methods are effective in reducing prostate cancer mortality is 
non-debatable. According to the World Health Organization (WHO), prostate cancer is 
among the top five types of cancer that cause the majority of cancer fatalities (WHO, 
2012). In the United States, prostate cancer is the second-leading cancer type, and in 
2007, was one of the leading causes of cancer death among all men, yielding 29,093 
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deaths related to prostate cancer (Centers for Disease Control and Prevention, 2011). As 
prostate cancer remains a prevalent problem, it is pertinent to critically examine the 
efficacy of the methods currently used to screen for prostate cancer.  
Common methods used to screen for prostate cancer in the clinical setting include 
both PSA testing and digital rectal exam (DRE). Prostate-specific antigen is a protein 
produced by the prostate gland that is a biologic marker of prostate cancer as well as 
benign prostate conditions (National Cancer Institute, 2009). PSA testing does not 
distinguish between benign and cancerous prostate conditions; however, levels elevated 
above set thresholds are a red flag for clinicians to pursue further testing (National 
Cancer Institute, 2009). According to the American Urological Society (AUA), prostate- 
specific antigen testing remains the single best test to detect prostate cancer in its early 
stages (2009, p.14). Furthermore, in combination with digital rectal examination, PSA 
testing may detect prostate cancer in its early stages at even higher rates (AUA, 2009, p. 
14). Why, then, is testing with PSA so controversial in practice? There are several 
medical uncertainties associated with it.  
First, there is great variability with the sensitivity and specificity of PSA testing. 
At lower cutoff points for detecting prostate cancer, specificity is sacrificed for 
sensitivity, increasing the risk of overdiagnosis. In addition to variable sensitivity and 
specificity of PSA testing, clinical guidelines differ in their recommendations for 
screening intervals and interpretations of test results. With no clear clinical pathway to 
follow and the recent contradictory evidence of the benefits and risks of prostate cancer 
screening with PSA testing, many clinicians have simply chosen to refrain from prostate 
cancer screening, raising ethical concerns regarding a patient’s right to be screened. One 
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must carefully review and critically appraise the current evidence of the efficacy of PSA 
testing to determine whether it significantly reduces prostate cancer mortality. 
 Critical Analysis of the Evidence Related to the Clinical Question 
Purpose  
 The studies by Andriole et al. (2009), Hugosson et al. (2010), Labrie et al. (1999a),  
 
and Schröder et al. (2009) share a common purpose of determining the impact of 
screening with prostate-specific antigen testing on prostate cancer mortality rates. The 
study by Sandblom, Varenhorst, Lofman, Rosell, & Carlsson (2004) is an exception 
because its purpose is to “to characterize prostate cancer detected in a population-based 
screening program” (p. 718) as well as to evaluate the efficacy of screening with PSA at 
three-year intervals. If the reader examines the primary outcomes measured in Sandblom 
et al.’s  (2004) study, the efficacy of PSA screening is measured in overall and cancer-
specific survival rates, an outcome similar to the aforementioned studies. The purpose of 
these studies reflects the purpose of the clinical question posed in this literature review. 
Research design 
 The five research studies utilized one type of experimental design- randomized 
controlled trials (RCT)-with varying strengths. The study designs were primarily cluster-
randomized controlled trials, where pre-existing males from specific populations were 
selected to be in either an intervention or control group. Of the randomized controlled 
trials, Schröder et al. (2009) and Hugosson et al. (2010) had the strongest designs, with 
large sample sizes, (power above .80), blinding to patient cause of death, and 
randomization before consent, increasing the generalizability of the study findings. In 
addition to these strengths, Schröder et al. (2009) utilized a central data center to ensure 
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quality data was obtained for the duration of the study. Sandblom et al. (2004) also had 
strengths, including randomization of participants prior to obtaining consent and control 
for the extraneous variable of treatment received by participants with a positive prostate 
cancer diagnosis. Strengths of Andriole et al.’s (2009) study included a large sample size 
and control for the extraneous variable of prostate cancer screening in the control group. 
A shared strength of all five studies was group equivalence, increasing the validity of the 
studies. Despite the strengths of these studies, limitations existed, with Labrie et al. 
(1999a), Andriole et al. (2009), and Sandblom et al. (2004) lacking a power analysis and 
blinding in their studies. Design limitations of all five studies included an absence of 
inter-rater reliability and instrumental validity scores as well as decreased generalizability 
of study findings due to the increased control associated with the study designs.  
Sampling 
 In all five of the research studies, older male adults without a previous or current 
prostate cancer diagnosis represented the populations studied. Purposive, stratified 
sampling was used to select the participants in each study. The population demographics 
among the studies were fairly consistent, with high group equivalence due to 
randomization of the study groups. All five studies had a male population, with ages 
ranging from 50-69 (except Andriole et al. (2009) and Schröder et al. (2009), with upper 
age limits in the mid to high 70s). Ethnicity was not included in the population 
demographics for any of the five studies, consequently decreasing the external validity of 
these studies’ findings. Attrition was addressed in some of the studies, with Schröder et 
al. (2009), Hugosson et al. (2010), and Sandblom et al. (2004) appropriately discussing 
the loss of their patients, which was largely due to immigration or death. The size of the 
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study samples varied according to study designs and limitations, and only Schröder et al. 
(2009) and Hugosson et al. (2010) justified their population size by a power analysis. 
Despite the lack of detailed demographic description in the studies, the following clinical 
and demographic characteristics of the studies, including lack of a previous or current 
prostate cancer diagnosis, all male subjects, and an age range of 50-80 years are a 
sufficient match for this literature review.  
Variables 
 Prostate-specific antigen testing was the primary screening intervention utilized in 
all of the studies with the exception of Sandblom et al. (2004), who chose to utilize the 
combination of PSA testing and DRE. Schröder et al. (2009) and Labrie et al. (1999a) 
also utilized digital rectal exam for prostrate cancer screening, however only for initial 
screening, and then only PSA testing after that. Andriole et al. (2009) screened with PSA 
and DRE separately, utilizing PSA testing for the first 6 years, then DRE for the last 4 
years of their studies. Although the screening method was consistent in most of the 
studies, the screening interval and PSA cutoff to signal further testing for prostate cancer 
varied. Labrie et al. (1999a) and Andriole et al. (2009) both utilized an annual PSA 
screening interval, with a PSA cutoff of >4.0 ng/ml in Andriole et al.’s study (2009), and 
a PSA cutoff of >3.0 ng/ml in Labrie et al.’s (1999a) study. Conversely, Schröder et al. 
(2009) conducted PSA testing every 4 years, with a PSA cutoff interval of >3.0- 4.0 
ng/ml. Hugosson et al. (2010) screened for prostate cancer with a free/total PSA test 
every 2 years, utilizing a PSA cutoff of >2.5-3.4 ng/ml for further diagnostic testing. 
Sandblom et al. (2004) utilized a screening interval of 3 years, with a PSA cutoff of >4.0 
ng/ml. The control used in all five studies was refraining from prostate cancer screening, 
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which was theoretically achieved by the control group not receiving invitations to screen. 
For the majority of the studies, the potential benefits of screening for prostate cancer 
were worth the risks. 
 The primary outcome measure of all of the studies was prostate cancer mortality 
(except Sandblom et al. (2004), the outcome of which was cancer-specific survival, an 
indirect measure of mortality). In addition to the measure of prostate cancer mortality 
rates, Hugosson et al. (2010) and Sandblom et al. (2004), examined the secondary 
outcome of cumulative prostate cancer incidence, Schröder et al. (2009) determined the 
number of people needed to screen and treat to prevent one prostate cancer-related death, 
Labrie et al. (1999a) measured life-years gained by the diagnosis and treatment of 
prostate cancer, and Andriole et al. (2009) determined the cost of prostate cancer 
diagnosis as well as prostate cancer incidence, staging, and survival from prostate cancer. 
Length of follow-up for measuring outcomes in the five studies varied, including 14 years 
for Hugosson et al. (2010), 9 years for Labrie et al. (1999a) and Schröder et al. (2009), 15 
years for Sandblom et al. (2004), and an interval of 7-14 years for Andriole et al. (2009). 
 Extraneous variables, whether known or detected, were present in all five studies.  
A known extraneous variable for Andriole et al. (2009) and Labrie et al. (1999a) was 
participation of the control group in prostate cancer screening, which was controlled for 
in statistical analyses. Another known extraneous variable that was considered in the 
2009 study design of Andriole et al. was the impact of different laboratory equipment on 
the consistency of PSA results, therefore Andriole et al. (2009) processed all PSA results 
through the same laboratory. Other known extraneous variables included bias related to 
prostate cancer treatment (Sandblom et al., 2004; Schröder et al., 2009) and the impact of 
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PSA testing as an established screening test on participant’s intention to screen (Labrie et 
al., 1999a), which were considered in the study designs. Extraneous variables that 
existed, but were not included in the studies included the impact of race on prostate 
cancer risk (except in Andriole et al. (2009)) and the effect of varying personnel 
administering digital rectal exams on the detection rate of prostate cancer. The failure to 
address these extraneous variables decreases the internal validity of the studies.    
Study measures 
 As mentioned in the previous section, the main outcome variable of the studies 
was prostate cancer mortality. It was determined by utilizing death registries, cancer 
registries, and mailed questionnaires. All five studies maintained a definition of prostate 
cancer mortality as death directly caused by prostate cancer, or death as a result of 
diagnostic procedures or treatments associated with prostate cancer. Cause of death was 
determined by committee review of medical records (Hugosson et al., 2010; Sandblom et 
al., 2004; Schröder et al., 2009), autopsy and pathology reports (Hugosson et al., 2010), 
and death certificates (Andriole et al., 2009). All of the methods used to determine 
prostate cancer mortality were established. Sandblom et al. (2004), however, were the 
only authors that discussed the validity of the cancer register utilized to determine 
mortality. With the exception of Sandblom et al. (2004), the other studies failed to 
discuss the reliability and validity of the methods utilized to determine prostate cancer 
mortality and survival rates as well as cause of death, weakening the internal validity of 
their studies.   
Statistical Analysis 
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 The statistical analyses used in the studies all differed from one another, yet each 
researcher utilized descriptive and inferential statistics appropriately. A strength of all the 
studies was their statistical significance levels were appropriately set at p ≤ .05. Andriole 
et al. (2009) and Sandblom et al. (2004), however, did not always designate p values for 
each finding, making their external validity questionable. The statistical analysis methods 
utilized in the studies include the following: Poisson regression analysis (Andriole et al., 
2009; Hugosson et al., 2010; Schröder et al., 2009), Cox regression models (Hugosson et 
al., 2010), the Nelsen-Aalen method (Hugosson et al., 2010; Schröder et al., 2009), a 
Kaplan Meir estimator (Hugosson et al., 2010; Sandblom et al., 2004), two-sided Fisher’s 
exact and Barnard’s tests (Labrie et al., 1999b), and log-rank tests (Sandblom et al., 
2004). All statistical tests utilized were appropriate for medical survival analysis as well 
as detecting significant differences between the intervention and control groups. Despite 
the appropriateness of these statistical analyses, their statistical conclusion validity is low 
and their risk for type II error is high (except in Hugosson et al. (2010) and Schröder et 
al.’s (2009) studies) because no official analysis to verify appropriate population size was 
conducted (Andriole et al., 2009; Labrie et al., 1999a) or their p value was simply not 
strong enough (Sandblom et al., 2004). The use of a power analysis and appropriate 
statistical analysis methods makes Schröder et al. (2009) and Hugosson et al.’s (2010) 
findings the highest in statistical conclusion validity.  
Findings 
 With the utilization of PSA testing at regular intervals, a significant reduction in 
the absolute risk for prostate cancer death after screening with PSA testing was found in 
Schröder et al. (2009) and Hugosson et al.’s (2010) studies. Similarly, Labrie et al. 
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(1999a) found regular PSA testing lead to a significant reduction in the incidence of 
prostate cancer deaths. Contrary to these findings, Sandblom et al. (2004) did not find a 
significant difference in prostate cancer-specific survival after screening with PSA testing 
and Andriole et al. (2009) did not find a significant difference between the screening and 
control groups in the reduction of prostate cancer mortality rates.  
Additional findings included the number of people that need to be screened 
(NNS) and treated (NNT) to prevent one prostate cancer-related death. Schröder et al. 
(2009) found the NNS and NNT were 1068 and 48 people and Hugosson et al. (2010) 
found the NNS and NNT were 293 and 12; numbers that appear significantly different, 
yet are quite similar with ratios applied (22:1 and 24:1). Additionally, Hugosson et al. 
(2010) found the control group had a significantly higher incidence of advanced prostate 
cancer than the screening group and Schröder et al. (2009) found screening with PSA 
testing significantly reduces the risk of diagnosis with metastatic prostate cancer. 
Sandblom et al.’s (2004) findings also demonstrated a significantly lower incidence of 
advanced tumor grades and metastases in the PSA testing intervention group than in the 
control group. Conversely, Andriole et al. (2009) determined there was no significant 
difference in the incidence of advanced (stage III of IV) prostate cancer in the screening 
and control groups.  
Other important results were related to the efficacy of screening with DRE and 
the cost of PSA screening and diagnosis of prostate cancer. For example, Labrie et al. 
(1999a) found that “14 percent of cancers were discovered by DRE in men with normal 
PSA” levels, however, “5,000 DRE screenings are required to diagnose 1 case of prostate 
cancer at follow-up visits” (p. 88). Labrie et al. (1999a) found the cost of screening and 
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diagnosing prostate cancer is actually less expensive in comparison to the cost of 
screening and diagnosing cervical and breast cancer. With the exception of Andriole et al. 
(2009) and Sandblom et al.’s (2004) findings, the pattern of evidence in the studies 
supports the effectiveness of prostate specific antigen screening in significantly reducing 
prostate cancer mortality.  
Synthesis “Answer” to the Clinical Question 
An analytical review of the five research studies suggests that there is a moderate 
amount of evidence that screening for prostate cancer utilizing PSA testing significantly 
reduces the absolute risk of prostate cancer mortality. Although only three of the five 
studies found PSA testing reduces prostate cancer mortality, the weight of evidence 
comes from the clinical trials conducted by Schröder et al. (2009) and Hugosson et al. 
(2010), as they have the highest level of statistical conclusion validity. Schröder et al. 
(2009) found utilizing PSA testing every four years with a PSA cutoff value of 3-4 ng/ml 
over a period of 9 years significantly reduces prostate cancer mortality. Hugosson et al. 
(2010) determined screening for prostate cancer with PSA testing at 2 years intervals 
with a PSA cutoff 2.5-3.4 over a 14-year period significantly reduces prostate cancer 
mortality. Labrie et al.’s (1999a) study, although it lacks a power analysis, is another 
strong contributor to the evidence-base for PSA screening because it is an RCT, used 
valid measures, and had a large group size. Labrie et al. (1999a) discovered, in the initial 
screening visit, digital rectal examination detected 14% of prostate cancers in men with 
normal PSA levels, however the effectiveness of DRE declined in follow-up 
appointments. Limitations of Schröder et al. (2009) and Hugosson et al.’s (2010) studies’ 
contribution to evidence-based practice is their lack of generalizability to the general 
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population of older male adults secondary to their tightly controlled study designs. 
Although the evidence provided by these studies is by no means conclusive, the 
statistically significant findings of Schröder et al. (2009) and Hugosson et al. (2010) 
demonstrate a need for replication or revision of these studies to provide further evidence 
to support the use of prostate-specific antigen testing in clinical practice.   
Implications for Practice 
Although the findings of Hugosson et al. (2010) and Schröder et al. (2009) carry a 
moderate weight of evidence supporting the use of PSA testing for prostate cancer 
screening, it is of critical importance that the clinical implications of their findings are 
carefully examined. It is crucial to consider how the findings of Hugosson et al. (2010) 
and Schröder et al. (2009) should be applied in practice when deciding what type of 
screening tests, screening intervals, and PSA cutoff points to utilize with prostate cancer 
screening. The findings of Hugosson et al. (2010) and Schröder et al. (2009) suggest that 
PSA testing used alone after the initial visit or throughout the course of testing is an 
effective screening test in reducing prostate cancer mortality. Although selecting PSA 
testing for prostate cancer screening is an initial step, the type of PSA test used in 
screening should also be considered as it could greatly impact the specificity of the test’s 
results (American Urological Association, 2009, p. 21). The American Urological Society 
(AUA) has discovered the use of a free/total PSA ratio has been found to “reduce the 
number of biopsies in men with serum PSA levels between 4.0 and 10.0 ng/ml”  
(2009, p. 21). Theoretically, utilizing a free/total prostate ratio would then also reduce 
unnecessary mental and physical harm to the patient as well. It is also imperative to 
consider that the addition of DRE to PSA testing in the initial screening visit was found 
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by Labrie et al. (1999a) to increase the sensitivity of screening for detecting prostate 
cancer. Reflecting on these results, it would be appropriate to give patients the 
recommendation for initially screening with DRE and a free/total PSA ratio, and then 
solely using PSA testing to screen for prostate cancer thereafter.  
In addition to the use of PSA testing as a primary prostate cancer screening test, 
Hugosson et al. (2010) and Schröder et al. (2009) also suggest screening with PSA testing 
at intervals of 2-4 years significantly reduces prostate cancer mortality. This is a very 
broad range of screening intervals, and when applying these results to a patient, a 
clinician must also consider whether the patient has a previous history of abnormal PSA 
results, their personal and family history of prostate cancer, and their symptoms. While 
the suggested screening interval of every 2-4 years suggests clinicians may be more 
liberal with screening, clinicians should utilize a screening interval that is individualized 
for the patient.  
Hugosson et al. (2010) and Schröder et al. (2009) provide an evidence base for an 
appropriate PSA threshold, an integral part of prostate cancer screening. The purpose of 
PSA threshold or cutoff values is they suggest an increased risk of prostate cancer and a 
need for further patient evaluation. Hugosson et al. (2010) and Schröder et al. (2009) 
imply that a PSA cutoff range of 2.5-4 ng/ml is clinically effective in detecting prostate 
cancer. This interval is fairly broad considering the difference of 1 ng/ml can 
dramatically change the sensitivity and specificity of PSA tests in detecting prostate 
cancer. The upper threshold of 4 ng/ml utilized by Schröder et al. (2009) has been found 
to have a sensitivity of 20% and a specificity of 60-70% (AUA, 2009, pp. 20-22). To 
increase the sensitivity and specificity of PSA tests, a lower PSA threshold for all men is 
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suggested (AUA, 2009, pp. 20-22), such as that used by Hugosson et al. (2010). To 
increase the specificity of PSA testing further, PSA thresholds can be age-adjusted, with 
lower PSA threshold levels utilized for younger men (AUA, 2009, p. 19). Considering 
the proven efficacy of the PSA thresholds utilized by Schröder et al. (2009) and 
Hugosson et al. (2010) and the evidence from the American Urological Association 
regarding the sensitivity and specificity of PSA thresholds, it would be advantageous for 
clinicians to use lower, age-adjusted PSA threshold levels for all men, such as the 
threshold of 2.5 ng/ml utilized by Hugosson et al. (2010).  
 Evidence regarding the length of follow-up for prostate cancer screening from 
Hugosson et al. (2010) and Schröder et al.’s (2009) studies also has important 
implications for clinical practice. Hugosson et al. (2010) and Schröder et al. (2009) found 
at 9 and 14 years of follow-up for prostate cancer screening, prostate cancer mortality is 
significantly reduced. These findings can be applied to clinical practice when clinicians 
are trying to determine when to commence or halt prostate cancer screening if the years 
of follow-up are viewed as male life expectancy. For example, if a an elderly man has a 
life-expectancy of less than 9 years, it may be advantageous for the patient to stop PSA 
testing, because the benefits of refraining from testing may outweigh the risks.  
The evaluation of current evidence with high statistical conclusion validity 
supports the use of prostate specific antigen testing in clinical practice to reduce prostate 
cancer mortality. While the particular formulas of PSA thresholds, screening intervals, 
and length of follow-up used by Schröder et al. (2009) and Hugosson et al. (2010) were 
both effective in reducing prostate cancer mortality, they varied quite a bit, meriting 
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consideration of further evidence such as recommendations from the American 
Urological Association (2009) prior to application of the results to clinical practice.  
Prostate cancer screening must be tailored to the individual, as their personal risk factors, 
history, and treatment preferences may shape the course of screening. Finally, given the 
strength of the evidence above, clinicians should at the very least offer their patients the 
choice to be screened for prostate cancer with PSA testing, because PSA testing may 
reduce their risk of developing advanced or even metastatic prostate cancer.  
Patient Education 
 After a patient is offered the choice to screen for prostate cancer, they should be 
presented with the current evidence regarding prostate cancer screening so they are well 
equipped to make an informed decision. If the patient chooses to undergo screening, they 
should be counseled that prostate cancer screening is tailored to the individual, with the 
clinician considering the patient’s history, risk factors, life expectancy, and comfort level 
for testing. The patient should be educated about the PSA test, the sensitivity and 
specificity of PSA thresholds, screening intervals, and the next steps taken after a positive 
PSA result (additional PSA tests and referral for fine-needle biopsy). Lastly, the clinician 
should emphasize the patient is the key decision-maker for their plan of care, and 
regardless of where the patient is in the screening process, the patient has the right to halt 
or refuse screening and treatment. 
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